-
-
-
-
-
-
-
BioMarin Completes Acquisition of Amicus Therapeutics
-
-
-
-
-
-
-
BioMarin prices $850 million senior notes offering at 5.5% yield
-
-
-
-
-
-
-
BioMarin to acquire Amicus Therapeutics for $4.8 billion
-
-
-
-
-
-
-
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Announces Acquisition of Inozyme Pharma (INZY) for $4 Per Share
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Announces Governance Enhancements and Value Creation Initiatives
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Ticks Higher for Second Day as It is Seen as Next Target in Sector
-
1,167,404 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

